Updated vaccine against ongoing mutations



[ad_1]

Updated vaccine against ongoing mutations

Modern is in the process of developing an updated vaccine that targets mutated variants of the coronavirus. In addition, the American biotech company has raised its global COVID-19 vaccine production target by 100 million doses this year.

Modern is developing a vaccine that will cure new mutations of the coronavirus. Stock Photography.Picture: Sue Ogrocki / AP / TT

Moderna revealed on Wednesday that the company has produced raw materials for an updated vaccine that will be crude in the variant of the virus that was first discovered in South Africa and may be more resistant to existing vaccines. The company has submitted the vaccine to the NIH of the US Public Health Agency for further study.

Modern is experimenting with several potential ways to combat new variants of the virus. Among other things, a dose that mixes the current vaccine with the new one and an updated extra dose that must be taken in addition to the current two-dose vaccine.

Moderna is also increasing its global vaccine production forecast for 2021 from 600 million doses to 700 million. The company is also investigating improvements to the manufacturing process that could increase production this year to 1 billion doses.

By 2022, Moderna expects to be able to produce approximately 1.4 billion doses with more investment in manufacturing.

[ad_2]